Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707328 · ClinicalTrials.gov registry record · Phase 1
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
A Phase 1 study, sponsored by The Cooper Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02707328 is a Phase 1 study that was terminated before completion, run by The Cooper Health System. The registered enrollment target is 30 participants.
The verdict
NCT02707328, a Phase 1 study, was terminated before completion, sponsored by The Cooper Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
Interventions
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- RADIATION CyberKnife
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02707328
The ClinicalTrials.gov registry entry for NCT02707328 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02707328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02707328 about?
NCT02707328 is a clinical study titled "Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)". This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
What is the current status of trial NCT02707328?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-01. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02707328?
The interventions under investigation include: Gemcitabine (DRUG), nab-paclitaxel (DRUG), CyberKnife (RADIATION).
Who is sponsoring clinical trial NCT02707328?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.